A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
- 08 Dec 2015 Interim analysis results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology